PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million

PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, announced the closing of a Series B extension, bringing the company’s total Series B financing to $77 million.

WilmerHale advised PAQ Therapeutics on the transaction.

The Series B extension builds on PAQ’s previously announced Series B financing. Proceeds from the financing will support the ongoing Phase 1 development of PT0253, PAQ’s KRAS G12D degrader, and PT0511, a pan-KRAS degrader.

The WilmerHale team was led by partner Andrea Sorrentino and included partner Stuart Falber and associate Amy O’Connell, with assistance from attorney Heidi Treiber and senior paralegal Cynthia Sullivan.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel